Fortrea Holdings (FTRE) Other Non Operating Income (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Other Non Operating Income came in at $3.5 million in Q2 2026, up 117.59% YoY from $1.6 million in Q2 2025, and down 63.92% on a QoQ basis from $9.7 million in Q1 2026.
Analysis
Fortrea Holdings (FTRE) Other Non Operating Income (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of Other Non Operating Income data on file, last reported at $3.5 million in Q2 2026.
- Quarterly Other Non Operating Income rose 117.59% year-over-year to $3.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $19.5 million (up 234.48% YoY) and the FY2025 annual result came in at -$26.9 million, down 226.29% from the prior year.
- Other Non Operating Income slipped to $3.5 million in Q2 2026, from $9.7 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $12.0 million in Q2 2022 to a low of -$19.9 million in Q2 2025.
- A 5-year average of $729411.8 and a median of $3.6 million in 2023 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2025 — Other Non Operating Income tumbled 321.11% — and 2026, when it jumped 273.21%.
- Tracing FTRE's Other Non Operating Income over 5 years: stood at -$19.0 million in 2022, then jumped by 112.11% to $2.3 million in 2023, then jumped by 169.57% to $6.2 million in 2024, then slumped by 80.65% to $1.2 million in 2025, then surged by 191.67% to $3.5 million in 2026.
- The last three Other Non Operating Income figures came in at $3.5 million (Q2 2026), $9.7 million (Q1 2026), and $1.2 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.70 Bn | 58.52 Bn | 1.37 Bn |
| 4 | Moderna | 57.56 Bn | 52.42 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.16 Bn | 35.06 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.63 Bn | 32.32 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.63 Bn | 27.79 Bn | - |
| 9 | Insmed | 27.73 Bn | 26.57 Bn | 358.27 Mn |
| 10 | Fortrea Holdings | 1.73 Bn | 1.56 Bn | 139.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.50 Mn |
| Mar 31, 2026 | 9.70 Mn |
| Dec 31, 2025 | 1.20 Mn |
| Sep 30, 2025 | 5.10 Mn |
| Jun 30, 2025 | -19.90 Mn |
| Mar 31, 2025 | -5.60 Mn |
| Dec 31, 2024 | 6.20 Mn |
| Sep 30, 2024 | 4.80 Mn |
| Jun 30, 2024 | 9.00 Mn |
| Mar 31, 2024 | -5.30 Mn |
| Dec 31, 2023 | 2.30 Mn |
| Sep 30, 2023 | 3.60 Mn |
| Dec 31, 2022 | -19.00 Mn |
| Sep 30, 2022 | 4.80 Mn |
| Jun 30, 2022 | 12.00 Mn |